| Gantenerumab: a novel human anti-Aβ antibody demonstrates sustained cerebral amyloid-β binding and elicits cell-mediated removal of human amyloid-β B Bohrmann, K Baumann, J Benz, F Gerber, W Huber, F Knoflach, ... Journal of Alzheimer's Disease 28 (1), 49-69, 2012 | 508 | 2012 |
| Mechanistic determinants of biotherapeutics absorption following SC administration WF Richter, SG Bhansali, ME Morris The AAPS journal 14, 559-570, 2012 | 341 | 2012 |
| Subcutaneous administration of biotherapeutics: an overview of current challenges and opportunities B Bittner, W Richter, J Schmidt BioDrugs 32, 425-440, 2018 | 315 | 2018 |
| 4-Aminoquinoline analogs of chloroquine with shortened side chains retain activity against chloroquine-resistant Plasmodium falciparum RG Ridley, W Hofheinz, H Matile, C Jaquet, A Dorn, R Masciadri, ... Antimicrobial agents and chemotherapy 40 (8), 1846-1854, 1996 | 282 | 1996 |
| Subcutaneous absorption of biotherapeutics: knowns and unknowns WF Richter, B Jacobsen Drug Metabolism and Disposition 42 (11), 1881-1889, 2014 | 230 | 2014 |
| CD20-TCB with obinutuzumab pretreatment as next-generation treatment of hematologic malignancies M Bacac, S Colombetti, S Herter, J Sam, M Perro, S Chen, R Bianchi, ... Clinical Cancer Research 24 (19), 4785-4797, 2018 | 190 | 2018 |
| Minipig as a potential translatable model for monoclonal antibody pharmacokinetics after intravenous and subcutaneous administration Y Zheng, DB Tesar, L Benincosa, H Birnböck, CA Boswell, D Bumbaca, ... MAbs 4 (2), 243-255, 2012 | 132 | 2012 |
| Analysis of erlotinib and its metabolites in rat tissue sections by MALDI quadrupole time‐of‐flight mass spectrometry L Signor, E Varesio, RF Staack, V Starke, WF Richter, G Hopfgartner Journal of mass spectrometry 42 (7), 900-909, 2007 | 131 | 2007 |
| Protection against lethal Escherichia coli bacteremia in baboons (Papio anubis) by pretreatment with a 55-kDa TNF receptor (CD120a)-Ig fusion protein, Ro 45-2081. KJ Van Zee, LL Moldawer, HS Oldenburg, WA Thompson, SA Stackpole, ... Journal of immunology (Baltimore, Md.: 1950) 156 (6), 2221-2230, 1996 | 101 | 1996 |
| Antimalarial activity of the bisquinoline trans-N1, N2-bis (7-chloroquinolin-4-yl) cyclohexane-1, 2-diamine: comparison of two stereoisomers and detailed evaluation of the S, S … RG Ridley, H Matile, C Jaquet, A Dorn, W Hofheinz, W Leupin, ... Antimicrobial agents and chemotherapy 41 (3), 677-686, 1997 | 77 | 1997 |
| Animal pharmacokinetics of the tumor necrosis factor receptor-immunoglobulin fusion protein lenercept and their extrapolation to humans WF Richter, H Gallati, CD Schiller Drug metabolism and disposition 27 (1), 21-25, 1999 | 70 | 1999 |
| Development of a subcutaneous formulation for trastuzumab–nonclinical and clinical bridging approach to the approved intravenous dosing regimen B Bittner, WF Richter, F Hourcade-Potelleret, C McIntyre, F Herting, ... Arzneimittelforschung 62 (09), 401-409, 2012 | 69 | 2012 |
| Protease-activation using anti-idiotypic masks enables tumor specificity of a folate receptor 1-T cell bispecific antibody M Geiger, KG Stubenrauch, J Sam, WF Richter, G Jordan, J Eckmann, ... Nature communications 11 (1), 1-14, 2020 | 57 | 2020 |
| Heparin chromatography as an in vitro predictor for antibody clearance rate through pinocytosis TE Kraft, WF Richter, T Emrich, A Knaupp, M Schuster, A Wolfert, ... MAbs 12 (1), 1683432, 2020 | 52 | 2020 |
| Interspecies scaling of interferon disposition and comparison of allometric scaling with concentration–time transformations T Lave, B Levet‐Trafit, AH Schmitt‐Hoffmann, B Morgenroth, W Richter, ... Journal of pharmaceutical sciences 84 (11), 1285-1290, 1995 | 49 | 1995 |
| Tissue distribution of a therapeutic monoclonal antibody determined by large pore microdialysis SB Jadhav, V Khaowroongrueng, M Fueth, MB Otteneder, W Richter, ... Journal of pharmaceutical sciences 106 (9), 2853-2859, 2017 | 44 | 2017 |
| Non-clinical pharmacokinetic/pharmacodynamic and early clinical studies supporting development of a novel subcutaneous formulation for the monoclonal antibody rituximab B Bittner, WF Richter, F Hourcade-Potelleret, F Herting, J Schmidt Drug research 64 (11), 569-575, 2014 | 39 | 2014 |
| Subcutaneous versus intravenous administration of rituximab: pharmacokinetics, CD20 target coverage and B-cell depletion in cynomolgus monkeys CP Mao, MR Brovarney, K Dabbagh, HF Birnböck, WF Richter, ... PLoS One 8 (11), e80533, 2013 | 38 | 2013 |
| Are biotransformation studies of therapeutic proteins needed? Scientific considerations and technical challenges S Schadt, S Hauri, F Lopes, MR Edelmann, RF Staack, R Villaseñor, ... Drug Metabolism and Disposition 47 (12), 1443-1456, 2019 | 34 | 2019 |
| 6-Alkoxy-5-aryl-3-pyridinecarboxamides, a new series of bioavailable cannabinoid receptor type 1 (CB1) antagonists including peripherally selective compounds S Röver, M Andjelkovic, A Bénardeau, E Chaput, W Guba, P Hebeisen, ... Journal of Medicinal Chemistry 56 (24), 9874-9896, 2013 | 33 | 2013 |
